Home » Pharma News (page 10)

Pharma News

Bial’s Zebinix meets primary endpoint in phase 3 study for patients with newly diagnosed partial-onset seizures

Bial’s Zebinix meets primary endpoint in phase 3 study for patients with newly diagnosed partial-onset seizures Bial has unveiled positive results for a pivotal phase 3 non-inferiority study comparing the efficacy and safety of eslicarbazepine acetate (ESL) to controlled release carbamazepine (CBZ-CR) as monotherapy in newly diagnosed adult patients with partial-onset seizures (POS). Bial director of research & development department ... Read More »

Can Pfizer finally orchestrate a winning megamerger after so many disappointments?

Can Pfizer finally orchestrate a winning megamerger after so many disappointments? Pfizer’s ($PFE) decision to buy Allergan ($AGN) wasn’t much of a surprise; the nominally Dublin-based Allergan was among the few buyout targets that could deliver CEO Ian Read‘s desired tax inversion. Nor is it surprising that Pfizer chose to rack up another megamerger, given its history of huge deals. ... Read More »

Heptares Therapeutics, Pfizer partner for GPCR-focused drug discovery

Heptares Therapeutics, Pfizer partner for GPCR-focused drug discovery Heptares Therapeutics and Pfizer have signed a drug discovery collaboration agreement, focused on G protein-coupled receptor (GPCR) targets across several therapeutic areas. Under the collaboration, the companies will research and develop potential new medicines directed at about 10 GPCR targets. Heptares will apply its GPCR structure-guided platform to help offer stabilized GPCRs ... Read More »

Mega Merger: Pfizer and Allergan to combine

Mega Merger: Pfizer and Allergan to combine Pfizer and Allergan to merge in a $160 billion deal Pfizer and Allergan has announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan in a stock transaction currently valued at $363.63 per Allergan share, for a ... Read More »

Dr Reddy’s barred from selling Esomeprazole Capsules in the US :

Dr Reddy’s barred from selling Esomeprazole Capsules in the US : Dr Reddy’s has received a Temporary Restraining Order (TRO) for Esomeprazole Capsules . The District Court of Delaware, USA, has passed an order granting a Temporary Restraining Order (TRO) with immediate effect on sales, delivery, transfer, or other disposition of Dr Reddy’s Laboratories’ generic esomeprazole product in the US ... Read More »

Arogya Finance and DRL collaborate to provide medical loans for financially weak

Arogya Finance and DRL collaborate to provide medical loans for financially weak Facilitates medical loans for Resof, a drug for treatment of Hepatitis C virus (HCV) infection and a few other therapies Arogya Finance has tied up with Dr Reddy’s Laboratories for providing medical loans for treatment of Hepatitis C. Reportedly, Arogya Finance will facilitate easy Equated Monthly Installments to patients ... Read More »

Torrent Pharma’s new Dahej plant commences operations

Torrent Pharma’s new Dahej plant commences operations The plant will mainly cater to the more regulated international markets such as the US, Brazil and Germany Torrent Pharma has commenced commercial operations at its new plant in Dahej. This is the company’s fifth formulation plant and the second API plant. The facility is being set up in two phases. The total investment ... Read More »

IIL opens ‘New Bovine Serum’ manufacturing unit in New Zealand

IIL opens ‘New Bovine Serum’ manufacturing unit in New Zealand The new plant can manufacture up to 300 tonnes of serum Indian Immunologicals Limited (IIL) has recently inaugurated its ‘New Bovine Serum’ manufacturing plant in New Zealand. The plant will produce key products like new born calf serum, adult bovine serum (NZ origin) and bulk bovine haemoglobin (NZ origin) for bio-pharmaceutical, ... Read More »

Alkem Laboratories gets SEBI’s nod for IPO

Alkem Laboratories gets SEBI’s nod for IPO As per the draft papers, the company will come out with a public offer of up to 12,853,442 equity shares Alkem Laboratories has received capital markets regulator Securities and Exchange Board of India’s (Sebi) approval to raise an estimated Rs 1,500-3,500-crore through an initial public offering (IPO). Alkem Laboratories filed the Draft Red Herring ... Read More »

GSK exercises option for inhaled therapeutics from Liquidia Technologies

GSK exercises option for inhaled therapeutics from Liquidia Technologies GlaxoSmithKline (GSK) has exercised an option that gives it the exclusive rights to research, develop and commercialize inhaled therapeutics derived from Liquidia Technologies’ PRINT technology. Under a collaboration and option agreement signed in June 2012, Liquidia was entitled to receive an upfront payment including cash and equity, R&D funding, and possible ... Read More »

BIGTheme.net • Free Website Templates - Downlaod Full Themes